Article thumbnail

R5 Clade C SHIV Strains with Tier 1 or 2 Neutralization Sensitivity: Tools to Dissect Env Evolution and to Develop AIDS Vaccines in Primate Models

By Nagadenahalli B. Siddappa, Jennifer D. Watkins, Klemens J. Wassermann, Ruijiang Song, Wendy Wang, Victor G. Kramer, Samir Lakhashe, Michael Santosuosso, Mark C. Poznansky, Francis J. Novembre, François Villinger, James G. Else, David C. Montefiori, Robert A. Rasmussen and Ruth M. Ruprecht
Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2908149
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2003). A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1.
  2. (2003). A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
  3. (2006). AIDS vaccine development and challenge viruses: getting real.
  4. (2005). Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.
  5. (2003). Antibody neutralization and escape by HIV-1.
  6. (2000). Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.
  7. (1992). Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.
  8. (2008). Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection.
  9. (2005). Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades
  10. (2007). Broadening our view of protective antibody responses against HIV.
  11. (2004). CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.
  12. (2006). Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques.
  13. (1999). Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.
  14. (2004). Development of the antibody response in acute HIV-1 infection.
  15. (1999). Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.
  16. (1995). Distribution of SIV in lymph nodes of serially sacrificed rhesus monkeys.
  17. (2003). Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.
  18. (2007). Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges.
  19. (2009). Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain.
  20. (2004). Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.
  21. (2009). Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.
  22. (2005). Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12:
  23. (2006). Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.
  24. (2005). Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant.
  25. (2004). Expansion of quasispecies diversity but no evidence for adaptive evolution of SHIV during rapid serial transfers among seronegative macaques.
  26. (2006). Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1.
  27. (1998). Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.
  28. (2006). Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.
  29. (2005). Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS.
  30. (2006). Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity.
  31. (2008). Importance of the V1/ V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.
  32. (1999). In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein.
  33. (1998). Intestinal intraepithelial lymphocytes are primed for gamma interferon and MIP-1beta expression and display antiviral cytotoxic activity despite severe CD4(+) T-cell depletion in primary simian immunodeficiency virus infection.
  34. (1995). Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
  35. (2009). Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection.
  36. (2007). Macaques infected with a CCR5-tropic simian/human immunodeficiency virus (SHIV) develop broadly reactive anti-HIV neutralizing antibodies.
  37. (2006). Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C env.
  38. (2007). N-linked glycan modifications in gp120 of human immunodeficiency virus type 1 subtype C render partial sensitivity to 2G12 antibody neutralization.
  39. (1999). Neutralization escape in human immunodeficiency virus type 1-infected longterm nonprogressors.
  40. (1990). Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera.
  41. (2009). Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection.
  42. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
  43. (2005). Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines.
  44. (2010). Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes.
  45. (2007). Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.
  46. (1999). Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation.
  47. (2000). Sensitive and robust one-tube real-time reverse transcriptasepolymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems.
  48. (2000). Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120.
  49. (2008). SHIV1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys.
  50. (1997). Specific N-linked and Olinked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.
  51. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
  52. (2000). Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.
  53. (2010). Targeting early infection to prevent HIV-1 mucosal transmission.
  54. (2008). The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
  55. (2004). The V1/ V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.
  56. (2010). Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.
  57. (2008). Toward an AIDS vaccine.
  58. (2003). Transmission, acute HIV-1 infection and the quest for strategies to prevent infection.
  59. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
  60. (2003). Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual.